Teriparatide effective than Alendronate for steroid-induced osteoporosisInjectable teriparatide (foreto) increases BMD (bone mineral density) by as much as two percent when compared to oral alendronate (fosamax) in a head-to-head comparison, according to a recent study.

It was remarked by Kenneth Saag, M.D., of the University of Alabama at Birmingham and his colleagues, that teriparatide was found in a relationship with enhanced improvements in the level of bone mineral density at the spine and hip.

Philip N. Sambrook, M.D., of the University of Sydney, said that teriparatide can prove to be a breakthrough option as a potential first-line therapy for steroid-Induced Osteoporosis as per the findings of Saag and his colleagues.

For informational purposes, teriparatide is currently approved for men and postmenopausal women with osteoporosis suffering from the high risk of fractures.